Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMIKE0O)

Drug Name
PRT1419 Drug Info
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMIKE0O

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) TTL53M6 MCL1_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DTT MCL1 7.695 6.404 5.954 6.82
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Melanoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DTT MCL1 1.06E-04 1.29 2.97
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04543305) A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Prelude Therapeutics.